Search | Clinical Trials Finder

Conditions: Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, carboplatin, epirubicin hydrochloride; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 3
States / cities: Bethesda, Maryland • Portsmouth, Virginia

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: Smoking Prevention Usual Care, Counseling Intervention; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Cavity SCC
Interventions: Nivolumab; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cavities of Teeth, Dental Decay
Interventions: Scotchbond™ Universal Plus Adhesive, Scotchbond™ Universal Adhesive; Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
Interventions: [64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection; Drug · Device · Procedure
Lead sponsor: Lumina Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Grand Rapids, Michigan • New York, New York

Conditions: Head and Neck Cancer
Interventions: DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry; Genetic
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions: Metformin, Durvalumab; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions: Intra-op PET/CT Specimen Scanner; Device
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
Interventions: questionnaire administration, survey administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Lenalidomide, liposomal doxorubicin; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: gemcitabine hydrochloride, tanespimycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Neoplasms
Interventions: Ultrasound; Procedure
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck
Interventions: Allovectin-7®; Genetic
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 10
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more

Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions: everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis; Drug · Procedure · Other + 2 more
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: thalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: herpes simplex thymidine kinase, ganciclovir; Biological · Drug
Lead sponsor: John Stoddard Cancer Center at Iowa Methodist Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: EF5, motexafin lutetium, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Floxuridine, Laboratory Biomarker Analysis, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Scottsdale, Arizona • Baltimore, Maryland • Rochester, Minnesota + 1 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
Interventions: amifostine trihydrate, cisplatin, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Larynx, LIP, Oral Cavity, Pharynx
Interventions: Metformin Hydrochloride, Doxycycline, Metformin +Doxycycline; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions: recombinant interferon alfa, isotretinoin; Biological · Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 6
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more

Search by objective public record fields.

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Scotchbond Universal Plus Compared to Scotchbond Universal for Posterior Class I & II Restorations With Filtek Universal

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Family Quality of Life Among Families With a Member Who is a Cancer Patient

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Ultrasound Targeting for the Lumpectomy Cavity

Phase II Trial of Allovectin-7® for Head and Neck Cancer

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer